2nd Oct 2020 15:45
EKF Diagnostics Holdings PLC - Cardiff-based diagnostics and central laboratory assay manufacturer - Performance for 2020 is still set to be in line with management expectations, due to significantly improved performance in the core business, based on October orders. In addition, continued orders for the PrimeStore MTM Covid-19 sample collection device. For October alone, group expects record month for revenue and profit. October results suggest strong performance in fourth quarter.
Current stock price: 60.85 pence
Year-to-date change: up 78%
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Ekf Diagnostics